We suspected auranofin would be a promising topical agent to treat diabetic pressure ulcers infected with MRSA as auranofin possesses potent antibacterial and antibiofilm activity in vitro and in vivo; additionally, auranofin reduced expression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) associated with impaired wound healing in uncomplicated cutaneous abscesses in mice16,20. The gene discussed is IL1B; the disease is Cutaneous abscess.